cilengitide + radiochemotherapy

Cilengitide + radiochemotherapy is a combination therapy involving cilengitide, a selective integrin inhibitor targeting αvβ3 and αvβ5 integrins, administered alongside standard chemoradiotherapy regimens. Cilengitide acts by inhibiting tumor angiogenesis and cell adhesion through blockade of these integrins, which are implicated in tumor growth and metastasis. In clinical studies, this combination has been primarily investigated for the treatment of newly diagnosed glioblastoma (especially in patients with unmethylated MGMT promoter) as well as locally advanced non-small-cell lung cancer. The chemoradiotherapy component typically includes temozolomide plus radiotherapy for glioblastoma or platinum-based chemotherapy plus radiotherapy for lung cancer. The combination aims to enhance antitumor efficacy by leveraging both direct cytotoxic effects (from chemo/radiation) and anti-angiogenic/anti-invasive mechanisms (from cilengitide). Clinical trials have shown that the regimen is generally well tolerated but with inconsistent improvements in survival outcomes[1][3][4][6].